Celanese Corporation CE
Composite 30/100; the shares have moved about 54% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 19/100 — a strong mark against it.
Valuation ranks 52/100 — a slight point in its favour.
Quality ranks 19/100 — a strong mark against it. Momentum ranks 22/100 — a strong mark against it. Balance-sheet strength ranks 25/100 — a moderate mark against it.
What the company does Celanese Corporation (CE) produces engineered polymers and chemicals used in automotive, electronics, medical, and industrial applications. Its Engineered Materials segment supplies high-performance polymers, while the Acetyl Chain segment produces acetic acid and related derivatives.
Key financials Key metrics include ROE -21.1%, ROA 2.4%, and ROCE -2.2%. Margins show gross 20.8%, operating 8.5%, and net -11.6%. Revenue growth is -2.2% while EPS growth is 28.2%. Leverage is high with Debt/Equity at 2.88 and Net debt/EBITDA at 7.08.
Stock health Momentum is weak: -31.11% over 3 months, -21.16% over 12 months, and -36.58% from the 52-week high. The RSI(14) is 41.40. Quality scores are poor (16.6/100), with Strength at 25.1 and Momentum at 24.8.
Price vs fair value CE trades at a PREMIUM of 28.80% versus the fair-value estimate of 31.89 and at a discount of 50.64% versus the analyst 12-month target of 67.50. - Analysts expect earnings growth ahead of the next earnings report (Zacks, 2026-07-28). - Sector peers show mixed performance, potentially limiting near-term upside (MT Newswires, 2026-07-30). - Weak quality and momentum scores (Sideravia) suggest limited investor enthusiasm.
Looking forward Forward P/E is 7.66, below the industry average, but high EV/EBITDA (42.18) and negative profitability metrics raise concerns. Analyst targets imply significant upside, but execution risks remain given weak fundamentals and high leverage.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.